Genzyme Corporation

Eberhard-Karls-Universitat Tubingen

Daniel Snell

Andreas Menrad

Gina Lacorcia

Clark Qun Pan

Huawei Qiu

Srinivas Shankara

Benjamin Kebble

Gregor Blank

Rupert Handgretinger

Karin Schilbach

The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.

Anti-&#x3b1;&#x3b2;TCR antibody

The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (&#x3b1;&#x3b2;-TCR). In particular, this disclosure relates to improved methods of use of a humanized anti-&#x3b1;&#x3b2;-TCR antibody, which is derived from the murine monoclonal antibody BMA031, in immunosuppressive therapy. Novel methods using humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-&#x3b1;&#x3b2;TCR antibodies and/or fragments thereof) are also provided. Novel methods using repetitive administration of humanized monoclonal antibodies and/or humanized monoclonal antibody fragments (e.g., anti-&#x3b1;&#x3b2;TCR antibodies and/or fragments thereof) to reduce &#x3b1;&#x3b2; T cells in the subject relative to &#x3b3;&#x3b4; cells in the subject are provided.

Methods for enhancing immunosuppressive therapy by multiple administration of &#x3b1;&#x3b2;TCR-binding polypeptide

Growing community of inventors

Thalwil, Switzerland

Daniel Snell